Investors

Discover Virbac's Statement on extra-financial performance

SALES 2020
934 M
59%
Companion
animals
41%
Food
producing
animals

(in € million)

Financial public release
& News

2021 fourth quarter consolidated sales

2022/01/19 - Financial public releases

Exceptional growth in annual revenue of +18.4% at comparable exchange rates and scope (+14.9% at constant rates and real scope), driven by remarkable performance in a very buoyant market

Read more

United States: Virbac announces the FDA approval of a tulathromycin injectable and a collaboration with Pharmgate

2021/12/08 - Financial public releases

Vignette_300X200_Porc_0000_P1033761.00_00_10_27.Still001.jpgVirbac's first steps into the U.S. food producing animal market.

Read more

Aquaculture : Virbac completes the acquisition of Centrovet

2021/11/05 - Financial public releases

vignette-corpo-centrovet.pngVirbac announces the acquisition of the remaining minority shares of the Centrovet group.

Read more

Events
Tuesday March 22

2021 results

From 2022/03/22

Read moreRead less

Tuesday March 22, 2022 after market close

2021 results
(quiet period from February 21, 2022)​

Wednesday March 23

SFAF meeting - 2021 financial & strategic information

From 2022/03/23

Read moreRead less

Wednesday March 23, 2022
SFAF meeting - 2021 financial & strategic information
Thursday April 14

2022 first quarter sales

From 2022/04/14

Read moreRead less

Thursday April 14, 2022 after market close

2022 first quarter sales
(quiet period from March 31, 2022)

Past Events
Wednesday January 19

2021 fourth quarter year sales

From 2022/01/19

Read moreRead less

Wednesday January 19, 2022 after market close

2021 fourth quarter year sales 
(quiet period from January 5, 2022)